Insider Selling: Albany Molecular Research major shareholder Sells 30,000 Shares of Stock (AMRI)
Albany Molecular Research (NASDAQ:AMRI) major shareholder Stuart M. Cable unloaded 30,000 shares of the company’s stock on the open market in a transaction dated Friday, August 1st. The stock was sold at an average price of $18.69, for a total value of $560,700.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
A number of analysts have recently weighed in on AMRI shares. Analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Separately, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.
Shares of Albany Molecular Research (NASDAQ:AMRI) traded up 0.48% on Monday, hitting $18.79. 321,021 shares of the company’s stock traded hands. Albany Molecular Research has a one year low of $9.71 and a one year high of $22.30. The stock’s 50-day moving average is $20.10 and its 200-day moving average is $16.49. The company has a market cap of $591.1 million and a price-to-earnings ratio of 61.72.
Albany Molecular Research (NASDAQ:AMRI) last released its earnings data on Tuesday, May 6th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.07. The company had revenue of $51.00 million for the quarter, compared to the consensus estimate of $62.19 million. Analysts expect that Albany Molecular Research will post $0.92 EPS for the current fiscal year.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.